PLX219145
GSE98212: A third generation therapeutic vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH
- Organsim human
- Type RNASEQ
- Target gene
- Project ARCHS4
Whole blood transcriptomic profiling indicated that CHAd63-KH induced innate immune responses characterized by an interferon signature and the presence of activated dendritic cells. SOURCE: Paul Kaye University of York
View on GEOView in PlutoKey Features
Enhance your research with our curated data sets and powerful platform features. Pluto Bio makes it simple to find and use the data you need.
Learn MoreAnalyze and visualize data for this experiment
Use Pluto's intuitive interface to analyze and visualize data for this experiment. Pluto's platform is equipped with an API & SDKs, making it easy to integrate into your internal bioinformatics processes.
Read about post-pipeline analysisView QC data and experiment metadata
View quality control data and experiment metadata for this experiment.
Request import of other GEO data
Request imports from GEO or TCGA directly within Pluto Bio.
Chat with our Scientific Insights team